Drug Information



Brand Name:Emcyt Trade Name:estramustine
FDA Approved For:EMCYT Capsules are indicated in the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate. Pediatric Use:Not discussed in FDA's Product label.
Carcinogen:Long-term continuous administration of estrogens in certain animal species increases the frequency of carcinomas of the breast and liver. Compounds structurally similar to EMCYT are carcinogenic in mice. Carcinogenic studies of EMCYT have not been conducted in man.Mutagen:Although testing by the Ames method failed to demonstrate mutagenicity for estramustine phosphate sodium, it is known that both estradiol and nitrogen mustard are mutagenic.
Manufacturer and/or Distributor:Pharmacia & Upjohn Company

Adverse Reactions:

For a complete list of adverse reactions please click on the link "More Information" for this drug.)

More Information